Published in Arterioscler Thromb Vasc Biol on January 13, 2011
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood (2012) 1.20
Translational research in immune senescence: assessing the relevance of current models. Semin Immunol (2012) 1.00
Chronic sleep fragmentation induces endothelial dysfunction and structural vascular changes in mice. Sleep (2014) 0.90
Bone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis development. PLoS One (2012) 0.83
Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma. Mol Cancer (2015) 0.78
Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice. Arterioscler Thromb Vasc Biol (2016) 0.76
Assessment of Venous Thrombosis in Animal Models. Arterioscler Thromb Vasc Biol (2015) 0.75
Enhanced Megakaryopoiesis and Platelet Activity in Hypercholesterolemic, B6-Ldlr-/-, Cdkn2a-Deficient Mice. Circ Cardiovasc Genet (2016) 0.75
Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol (2007) 16.55
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
Ink4a/Arf expression is a biomarker of aging. J Clin Invest (2004) 8.30
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature (2006) 8.06
Aging, progenitor cell exhaustion, and atherosclerosis. Circulation (2003) 5.19
Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet (2010) 3.89
Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature (2010) 3.77
Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest (1996) 2.97
Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol (2009) 2.79
INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One (2009) 2.77
Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell (2009) 2.58
Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost (2007) 2.56
Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol (2007) 2.46
Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell (2009) 2.21
Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood (2010) 2.10
Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood (2006) 2.06
Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. Exp Gerontol (2005) 1.96
Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol (2008) 1.93
Cellular senescence and organismal aging. Mech Ageing Dev (2008) 1.92
Vascular endothelial senescence: from mechanisms to pathophysiology. J Appl Physiol (1985) (2008) 1.87
Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol (2007) 1.74
Ink4a/Arf links senescence and aging. Exp Gerontol (2004) 1.70
Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev (2009) 1.62
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest (2005) 1.58
In vivo thrombus formation in murine models. Circ Res (2007) 1.54
Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood (2000) 1.47
Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J Thromb Haemost (2009) 1.46
An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb Res (2005) 1.43
Microvascular thrombosis models in venules and arterioles in vivo. Microcirculation (2005) 1.34
Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation (1998) 1.29
The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis. Blood (2008) 1.26
Epidemiology of venous thromboembolism. Ann Surg (1977) 1.19
Erythrocyte hemolysis and hemoglobin oxidation promote ferric chloride-induced vascular injury. J Biol Chem (2009) 1.10
Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. Thromb Haemost (2009) 1.07
Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res (2010) 1.05
Thrombin generation in patients after acute deep-vein thrombosis. Thromb Haemost (2008) 1.02
Mechanisms of endothelial senescence. Exp Physiol (2008) 1.01
Transendothelial migration of ferric ion in FeCl3 injured murine common carotid artery. Thromb Res (2005) 1.01
Molecular mechanisms for the senescent cell cycle arrest. J Investig Dermatol Symp Proc (1998) 1.00
Nitric oxide and endothelial cellular senescence. Pharmacol Ther (2008) 0.99
Venous thrombosis in the elderly: more questions than answers. Blood (2007) 0.98
Aging accelerates endotoxin-induced thrombosis : increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. Am J Pathol (2002) 0.97
Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-induced lethality in mice in vivo. Arterioscler Thromb Vasc Biol (1997) 0.97
Aging is associated with impaired thrombus resolution in a mouse model of stasis induced thrombosis. Thromb Res (2009) 0.96
Pathophysiology of venous thrombosis, thrombophilia, and the diagnosis of deep vein thrombosis-pulmonary embolism in the elderly. Clin Geriatr Med (2006) 0.94
Overview of murine thrombosis models. Thromb Res (2008) 0.91
Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood (2002) 0.91
A profibrotic effect of plasminogen activator inhibitor type-1 (PAI-1) in the heart. Exp Biol Med (Maywood) (2009) 0.89
Anisodamine counteracts lipopolysaccharide-induced tissue factor and plasminogen activator inhibitor-1 expression in human endothelial cells: contribution of the NF-kappa b pathway. J Vasc Res (2001) 0.89
In vivo models for the evaluation of antithrombotics and thrombolytics. Methods Mol Biol (2010) 0.86
Inflammation and endothelial dysfunction: intimate companions in the pathogenesis of vascular disease? Clin Sci (Lond) (2004) 0.84
Venous and arterial thrombosis: epidemiology and risk factors at various ages. Maturitas (2004) 0.84
The search for biomarkers of aging: next stop INK4a/ARF locus. Sci Aging Knowledge Environ (2004) 0.82
A survey of venous thrombosis models. Methods Mol Med (2004) 0.81
Lipopolysaccharide augments venous and arterial thrombosis in the mouse. Thromb Res (2008) 0.81
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
The regulation of INK4/ARF in cancer and aging. Cell (2006) 8.75
Ink4a/Arf expression is a biomarker of aging. J Clin Invest (2004) 8.30
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature (2006) 8.06
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA (2012) 5.16
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet (2010) 3.89
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell (2013) 3.04
Arp2/3 is critical for lamellipodia and response to extracellular matrix cues but is dispensable for chemotaxis. Cell (2012) 2.98
INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One (2009) 2.77
RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25
Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell (2009) 2.21
Somatic LKB1 mutations promote cervical cancer progression. PLoS One (2009) 2.21
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
Expression of p16(INK4a) prevents cancer and promotes aging in lymphocytes. Blood (2011) 2.16
Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood (2010) 2.10
Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci U S A (2002) 2.03
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst (2014) 1.96
Cancer: crime and punishment. Nature (2005) 1.91
CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol Cell Biol (2008) 1.82
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst (2012) 1.81
Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond) (2010) 1.78
Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/- mice. Circ Res (2011) 1.78
Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest (2010) 1.74
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res (2012) 1.74
Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood (2011) 1.73
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica (2008) 1.67
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res (2007) 1.62
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A (2007) 1.61
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest (2009) 1.49
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell (2012) 1.49
Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci U S A (2002) 1.46
CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest (2007) 1.45
Major burn injury is not associated with acute traumatic coagulopathy. J Trauma Acute Care Surg (2013) 1.43
Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation (2009) 1.40
A mouse model of human oral-esophageal cancer. J Clin Invest (2002) 1.40
p38MAPK controls expression of multiple cell cycle inhibitors and islet proliferation with advancing age. Dev Cell (2009) 1.40
HMGA2, microRNAs, and stem cell aging. Cell (2008) 1.38
Review: a meta-analysis of GWAS and age-associated diseases. Aging Cell (2012) 1.36
ROS as a tumour suppressor? Nat Cell Biol (2006) 1.33
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J (2002) 1.33
Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A (2003) 1.32
Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. Cancer Res (2007) 1.32
Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem (2002) 1.29
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov (2013) 1.27
The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis. Blood (2008) 1.26
Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest (2013) 1.24
Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol (2006) 1.24
Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp Cell Res (2006) 1.22
Coming of age: molecular drivers of aging and therapeutic opportunities. J Clin Invest (2013) 1.22
Expression of p16(INK4a) as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. Aging Cell (2012) 1.21
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood (2012) 1.20
Cdkn2a is an atherosclerosis modifier locus that regulates monocyte/macrophage proliferation. Arterioscler Thromb Vasc Biol (2011) 1.16
Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res (2013) 1.16
Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma. Cancer Res (2003) 1.12
Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans. FEBS J (2005) 1.12
LKB1 and lung cancer: more than the usual suspects. Cancer Res (2008) 1.11
Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol (2007) 1.11
PAR-1 contributes to the innate immune response during viral infection. J Clin Invest (2013) 1.09
Tumor suppressor mechanisms in immune aging. Curr Opin Immunol (2009) 1.08
Mature breast adipocytes promote breast cancer cell motility. Exp Mol Pathol (2012) 1.07
Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res (2010) 1.05
Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J Biol Chem (2002) 1.04
Effect of locked-nucleic acid on a biologically active g-quadruplex. A structure-activity relationship of the thrombin aptamer. Int J Mol Sci (2008) 1.03
Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1. PPAR Res (2009) 1.01
Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res (2004) 0.99
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res (2014) 0.98
PARP and cancer--if it's broke, don't fix it. N Engl J Med (2011) 0.96
A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1. Oncogene (2002) 0.96
Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet. Am J Pathol (2011) 0.96
RAS unplugged: negative feedback and oncogene-induced senescence. Cancer Cell (2006) 0.96
Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes. J Biol Chem (2004) 0.96
Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. Blood (2010) 0.95
Loss of Arp2/3 induces an NF-κB-dependent, nonautonomous effect on chemotactic signaling. J Cell Biol (2013) 0.93
RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. FEBS Lett (2004) 0.93
Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF. J Natl Cancer Inst (2004) 0.93
p16INK4a reporter mice reveal age-promoting effects of environmental toxicants. J Clin Invest (2013) 0.92
Cancer biology: gone but not forgotten. Nature (2007) 0.92
Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem (2010) 0.92
Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays (2007) 0.92
Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol (2006) 0.92